Topic: Subcutaneous

The FDA issued an emergency use authorization allowing the monkeypox vaccine to be delivered subcutaneously at one-fifth of the standard dose to stretch limited supplies. This "dose-sparing" strategy is based on a single study, raising concerns among patients about its actual effectiveness. The change from intramuscular to under-the-skin injection is criticized as an experimental move on the public without sufficient data.